Salem Radio Network News Sunday, November 28, 2021

Health

U.S. FDA approves Takeda’s drug for post-transplant infection

(Reuters) – The U.S. Food and Drug Administration said on Tuesday it had approved Takeda Pharmaceutical Co Ltd’s Livtencity for a common type of post-transplant infection.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)

Previous
Next

Editorial Cartoons

View More »

Steve Breen
Sun, Nov 21, 2021

X CLOSE